K220272

Substantially Equivalent

cobas pulse blood glucose monitoring system

Applicant: Roche Diagnostics
Product code: PZI
Advisory panel: Clinical Chemistry
Date received: 2022-01-31
Decision date: 2024-04-26
Decision: Substantially Equivalent
Clearance type: Dual Track
Location: Indianapolis, IN, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.